Publications by authors named "Adrien Mouren"
Why and how citrate may sensitize malignant tumors to immunotherapy.
Drug Resist Updat
January 2025
Article Synopsis
- Immunotherapy, particularly when combined with chemotherapy, has shown limited effectiveness against solid tumors due to factors like cancer cells promoting immune cell exhaustion through nutrient diversion in the tumor microenvironment (TME).
- The authors suggest using high doses of sodium citrate (SCT) alongside immune checkpoint inhibitors (ICIs) to inhibit cancer cell metabolism and enhance anti-tumor immune responses, as preclinical studies indicate SCT can reduce cancer growth and improve chemotherapy outcomes.
- SCT works by increasing available glucose for immune cells and lowering lactic acid levels in the TME, which may enhance T cell activity and repolarize macrophages, indicating its potential to significantly boost the effectiveness of current immunotherapies in clinical settings.
De novo germline pathogenic variants (gPV) of the BReast CAncer 1 (BRCA1) gene are very rare. Only a few have been described up to date, usually in patients with a history of ovarian or breast cancer. Here, we report the first case of an incidental de novo BRCA1 germline pathogenic variant which was identified within the framework of the Plan France Médecine Génomique (PFMG) 2025 French national tumor sequencing program.
View Article and Find Full Text PDFPluripotent mouse embryonic stem cells maintain their identity throughout virtually infinite cell divisions. This phenomenon, referred to as self-renewal, depends on a network of sequence-specific transcription factors (TFs) and requires daughter cells to accurately reproduce the gene expression pattern of the mother. However, dramatic chromosomal changes take place in mitosis, generally leading to the eviction of TFs from chromatin.
View Article and Find Full Text PDF